Research

Hormonal

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.

GoodSupportsHIGH confidence
At 52 weeks, semaglutide plus D&E and D&E alone reversed prediabetes in 80% and 12% of patients, and decreased BMI by 13.9% and 2.7%, respectively.
Mafalda Ramos et al. · Journal of Medical Economics · 2025

Why this rating

Based on a Phase 3 randomized controlled trial (STEP 10) with a clear treatment arm, though the 52-week duration is short for hard cardiovascular endpoints.

Source

The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England

Mafalda Ramos et al. · Journal of Medical Economics · 2025

DOI 10.1080/13696998.2025.2575692

clinical_guideline · n=207Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →